KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Goodwill & Intangibles (2019 - 2025)

Royalty Pharma's Goodwill & Intangibles history spans 3 years, with the latest figure at $924.6 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles changed N/A year-over-year to $924.6 million; the TTM value through Dec 2025 reached $924.6 million, changed N/A, while the annual FY2025 figure was $924.6 million, N/A changed from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $924.6 million at Royalty Pharma, roughly flat from $924.6 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $924.6 million in Q2 2025 and bottomed at $5.7 million in Q4 2021.